CD276-targeting chimeric antigen receptor with CD28 and 4-1BB as costimulatory structural domain and application of CD276-targeting chimeric antigen receptor

A chimeric antigen receptor and costimulatory domain technology, applied in the field of chimeric antigen receptor T cells and preparation, and chimeric antigen receptor, can solve the problem of limited research on killing activity, and achieve strong killing activity and durability. , the effect of maintaining vitality and lethality

Active Publication Date: 2022-02-01
SHENZHEN INST OF ADVANCED TECH +1
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Currently, there is limited research on the killing activity of CD276-targeting CAR-T cells against hepatocellular carcinoma and other malignant tumors that highly express CD276

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CD276-targeting chimeric antigen receptor with CD28 and 4-1BB as costimulatory structural domain and application of CD276-targeting chimeric antigen receptor
  • CD276-targeting chimeric antigen receptor with CD28 and 4-1BB as costimulatory structural domain and application of CD276-targeting chimeric antigen receptor
  • CD276-targeting chimeric antigen receptor with CD28 and 4-1BB as costimulatory structural domain and application of CD276-targeting chimeric antigen receptor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0055] In order to enable those skilled in the art to better understand the solutions of the present invention, the following will clearly and completely describe the technical solutions in the embodiments of the present invention in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only It is an embodiment of a part of the present invention, but not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by persons of ordinary skill in the art without making creative efforts shall fall within the protection scope of the present invention.

[0056] It should be noted that the terms "first" and "second" in the description and claims of the present invention and the above drawings are used to distinguish similar objects, but not necessarily used to describe a specific sequence or sequence. It is to be understood that the data so used are interchangeable under appropriate ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a CD276-targeting chimeric antigen receptor with CD28 and 4-1BB as costimulatory structural domains and application of the CD276-targeting chimeric antigen receptor, and belongs to the technical field of biological medicine. According to the CD276-targeting chimeric antigen receptor T cell disclosed by the invention, CD28 and 4-1BB are taken as costimulatory structural domains, so that the CD276-targeting chimeric antigen receptor T cell has strong killing activity on positive tumor cell lines expressing CD276, has stronger killing activity and durability in vivo, and is beneficial to the generation of memory phenotype T cells. In-vitro function tests show that the CD276-targeted chimeric antigen receptor T cell has killing activity on CD276 positive liver cancer cell lines.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and specifically relates to CD276-targeting chimeric antigen receptors with CD28 and 4-1BB co-stimulatory domains, chimeric antigen receptor T cells, preparation methods and applications. Background technique [0002] Hepatocellular carcinoma is a malignant tumor that seriously threatens human health. Current treatments for hepatocellular carcinoma include chemotherapy, radiotherapy, hepatectomy, ablation therapy, targeted therapy such as Sorafenib, antibody therapy such as immune checkpoint inhibitors, Vascular endothelial growth factor receptor inhibitors, these treatment methods can not achieve good therapeutic effect. [0003] Chimeric antigen receptor T cell therapy is a new type of immune cell therapy, which has the function of specifically and efficiently killing tumor cells expressing corresponding antigens. CD276, also known as B7-H3, is a type of transmembrane protein belonging to ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C12N15/62C12N5/10C12N15/867A61K39/00A61P35/00
CPCC07K16/2827C07K14/70517C07K14/70521C07K14/70578C07K14/7051C12N5/0636C12N15/86A61K39/001111A61P35/00C07K2317/622C07K2319/03C07K2319/33C07K2319/60C07K2319/74C12N2510/00C12N2740/15043C12N2800/107A61K2039/5156A61K2039/844
Inventor 万晓春曹国政
Owner SHENZHEN INST OF ADVANCED TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap